Literature DB >> 25646644

Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.

Shidong Chu1, Hardeep Kaur1, Ariana Nemati1, Joseph D Walsh1,2, Vivian Partida1, Shao-Qing Zhang2,3, Miriam Gochin1,2.   

Abstract

The conformational rearrangement of N- and C-heptad repeats (NHR, CHR) of the HIV-1 glycoprotein-41 (gp41) ectodomain into a trimer of hairpins triggers virus-cell fusion by bringing together membrane-spanning N- and C-terminal domains. Peptides derived from the NHR and CHR inhibit fusion by targeting a prehairpin intermediate state of gp41. Typically, peptides derived from the CHR are low nanomolar inhibitors, whereas peptides derived from the NHR are low micromolar inhibitors. Here, we describe the inhibitory activity of swapped-domain gp41 mimics of the form CHR-loop-NHR, which were designed to form reverse hairpin trimers exposing NHR grooves. We observed low nanomolar inhibition of HIV fusion in constructs that possessed the following properties: an extended NHR C-terminus, an exposed conserved hydrophobic pocket on the NHR, high helical content, and trimer stability. Low nanomolar activity was independent of CHR length. CD studies in membrane mimetic dodecylphosphocholine micelles suggested that bioactivity could be related to the ability of the inhibitors to interact with a membrane-associated prehairpin intermediate. The swapped-domain design resolves the problem of unstable and weakly active NHR peptides and suggests a different mechanism of action from that of CHR peptides in inhibition of HIV-1 fusion.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25646644      PMCID: PMC4562464          DOI: 10.1021/cb501021j

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  62 in total

Review 1.  Interaction of membrane proteins and lipids with solubilizing detergents.

Authors:  M le Maire; P Champeil; J V Moller
Journal:  Biochim Biophys Acta       Date:  2000-11-23

Review 2.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

3.  Potent D-peptide inhibitors of HIV-1 entry.

Authors:  Brett D Welch; Andrew P VanDemark; Annie Heroux; Christopher P Hill; Michael S Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

4.  Dissociation of the trimeric gp41 ectodomain at the lipid-water interface suggests an active role in HIV-1 Env-mediated membrane fusion.

Authors:  Julien Roche; John M Louis; Alexander Grishaev; Jinfa Ying; Adriaan Bax
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

5.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

6.  The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure.

Authors:  C Wild; T Greenwell; D Shugars; L Rimsky-Clarke; T Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1995-03       Impact factor: 2.205

7.  Membrane-induced conformational change during the activation of HIV-1 gp41.

Authors:  Y Kliger; S G Peisajovich; R Blumenthal; Y Shai
Journal:  J Mol Biol       Date:  2000-08-25       Impact factor: 5.469

8.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.

Authors:  Takeshi Naito; Kazuki Izumi; Eiichi Kodama; Yasuko Sakagami; Keiko Kajiwara; Hiroki Nishikawa; Kentaro Watanabe; Stefan G Sarafianos; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

View more
  3 in total

1.  Biophysical studies of HIV-1 glycoprotein-41 interactions with peptides and small molecules - Effect of lipids and detergents.

Authors:  Guangyan Zhou; Shidong Chu; Aditya Kohli; Francis C Szoka; Miriam Gochin
Journal:  Biochim Biophys Acta Gen Subj       Date:  2020-09-02       Impact factor: 3.770

Review 2.  Designing helical peptide inhibitors of protein-protein interactions.

Authors:  Raheleh Rezaei Araghi; Amy E Keating
Journal:  Curr Opin Struct Biol       Date:  2016-04-25       Impact factor: 6.809

3.  A targeted covalent small molecule inhibitor of HIV-1 fusion.

Authors:  Guangyan Zhou; Li He; Kathy H Li; Cássio C S Pedroso; Miriam Gochin
Journal:  Chem Commun (Camb)       Date:  2021-05-06       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.